MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (trial in Progress)
Clinical Lymphoma Myeloma & Leukemia（2022）
Key words
MCL,pirtobrutinib,BTKi,mantle cell lymphoma,clinical trial,phase III,trial-in-progress
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined